These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8251869)

  • 21. A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects.
    Liester MB
    Curr Drug Abuse Rev; 2014; 7(3):146-56. PubMed ID: 25563445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions.
    White FJ
    Pharmacol Biochem Behav; 1986 Feb; 24(2):365-79. PubMed ID: 3952127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacology of lysergic acid diethylamide: a review.
    Passie T; Halpern JH; Stichtenoth DO; Emrich HM; Hintzen A
    CNS Neurosci Ther; 2008; 14(4):295-314. PubMed ID: 19040555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent palinopsia following ingestion of lysergic acid diethylamide (LSD).
    Kawasaki A; Purvin V
    Arch Ophthalmol; 1996 Jan; 114(1):47-50. PubMed ID: 8540850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is LSD toxic?
    Nichols DE; Grob CS
    Forensic Sci Int; 2018 Mar; 284():141-145. PubMed ID: 29408722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT
    De Gregorio D; Posa L; Ochoa-Sanchez R; McLaughlin R; Maione S; Comai S; Gobbi G
    Pharmacol Res; 2016 Nov; 113(Pt A):81-91. PubMed ID: 27544651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration.
    Nichols CD; Garcia EE; Sanders-Bush E
    Brain Res Mol Brain Res; 2003 Mar; 111(1-2):182-8. PubMed ID: 12654518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide.
    Burris KD; Sanders-Bush E
    Mol Pharmacol; 1992 Nov; 42(5):826-30. PubMed ID: 1359397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic Similarities and Differences Among Hallucinogens.
    Waters K
    J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S100-S113. PubMed ID: 34396556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unfavourable reactions to LSD: a review and analysis of the available case reports.
    Smart RG; Bateman K
    Can Med Assoc J; 1967 Nov; 97(20):1214-21. PubMed ID: 4862277
    [No Abstract]   [Full Text] [Related]  

  • 31. d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.
    De Gregorio D; Comai S; Posa L; Gobbi G
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
    Buckholtz NS; Zhou DF; Freedman DX; Potter WZ
    Neuropsychopharmacology; 1990 Apr; 3(2):137-48. PubMed ID: 1969270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lysergic acid diethylamide causes mouse retinal damage by up-regulating p-JAK1/p-STAT1.
    Chen K; He X; Li C; Ou Y; Li Y; Lai J; Lv M; Li X; Ran P; Li Y
    Cutan Ocul Toxicol; 2020 Jun; 39(2):106-110. PubMed ID: 32064962
    [No Abstract]   [Full Text] [Related]  

  • 34. Dual actions of lysergic acid diethylamide tartrate (LSD), 2-bromo-D-lysergic acid diethylamide bitartrate (BOL) and methysergide on dorsal root potentials evoked by stimulation of raphe nuclei.
    Larson AA; Chinn C; Proudfit HK; Anderson EG
    J Pharmacol Exp Ther; 1981 Apr; 217(1):99-104. PubMed ID: 6110778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age-specific patterns of hallucinogen use in the US population: an analysis using generalized additive models.
    Chilcoat HD; Schütz CG
    Drug Alcohol Depend; 1996 Dec; 43(3):143-53. PubMed ID: 9023070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do hallucinogens cause residual neuropsychological toxicity?
    Halpern JH; Pope HG
    Drug Alcohol Depend; 1999 Feb; 53(3):247-56. PubMed ID: 10080051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis.
    Sadzot B; Baraban JM; Glennon RA; Lyon RA; Leonhardt S; Jan CR; Titeler M
    Psychopharmacology (Berl); 1989; 98(4):495-9. PubMed ID: 2505289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of the hallucinogenic drugs LSD-25 and mescaline on the electroretinogram.
    APTER JT; PFEIFFER CC
    Ann N Y Acad Sci; 1957 Mar; 66(3):508-13; discussion, 513-4. PubMed ID: 13425239
    [No Abstract]   [Full Text] [Related]  

  • 39. The paradoxical psychological effects of lysergic acid diethylamide (LSD).
    Carhart-Harris RL; Kaelen M; Bolstridge M; Williams TM; Williams LT; Underwood R; Feilding A; Nutt DJ
    Psychol Med; 2016 May; 46(7):1379-90. PubMed ID: 26847689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adolescent and adult time trends in US hallucinogen use, 2002-19: any use, and use of ecstasy, LSD and PCP.
    Livne O; Shmulewitz D; Walsh C; Hasin DS
    Addiction; 2022 Dec; 117(12):3099-3109. PubMed ID: 35978453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.